Reference(s)
Click here to return to the Reference Table

Descriptor: Animal models


Acute Myelogenous Leukemia

Adult T Cell Leukemia

Bladder

Reference Number: 4
Bellusci, S. et al. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene 9, 1091-9 (1994).
PubMed link      E-mail link

Reference Number: 5
Inui, M. et al. Enhanced gene expression of transforming growth factor-alpha and c-met in rat urinary bladder cancer. Urol Res 24, 55-60 (1996).
PubMed link      E-mail link

Reference Number: 1771
Dang Q, Song W, Xu D, Ma Y, Li F, Zeng J, Zhu G, Wang X, Chang LS, He D, Li L. Kaempferol suppresses bladder cancer tumor growth by inhibiting cell proliferation and inducing apoptosis. Mol Carcinog. 54, 831-40 (2015)
PubMed link      E-mail link

Breast

Reference Number: 19
Fan, S. et al. Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. Oncogene 17, 131-41 (1998).
PubMed link      E-mail link

Reference Number: 20
Farinelle, S. et al. Characterization of biological features and chemosensitivity of a new experimental lung metastasis model originating from the MXT mouse mammary adenocarcinoma. Anticancer Res 19, 1171-80 (1999).
PubMed link      E-mail link

Reference Number: 21
Firon, M. et al. Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells. Oncogene 19, 2386-97 (2000).
PubMed link      E-mail link

Reference Number: 24
Lamszus, K. et al. Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice. Lab Invest 76, 339-53 (1997).
PubMed link      E-mail link

Reference Number: 25
Liang, T. J., Reid, A. E., Xavier, R., Cardiff, R. D. & Wang, T. C. Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J Clin Invest 97, 2872-7 (1996).
PubMed link      E-mail link

Reference Number: 26
Rosen, E. M. et al. Scatter factor modulates the metastatic phenotype of the EMT6 mouse mammary tumor. Int J Cancer 57, 706-14 (1994).
PubMed link      E-mail link

Reference Number: 27
Shaharabany, M. et al. In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs and breast tumors. Cancer Res 61, 4873-8 (2001).
PubMed link      E-mail link

Reference Number: 28
Takayama, H. et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 94, 701-6 (1997).
PubMed link      E-mail link

Reference Number: 217
Gallego, M.I., Bierie, B. & Henninghausen, L. Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways.  Oncogene 22:8498-508 (2003).
PubMed link      E-mail link

Reference Number: 294
Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, Comoglio PM. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6, 61-73 (2004)
PubMed link      E-mail link

Reference Number: 342
Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, Comoglio PM, Michieli P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest. 114, 1418-32 (2004)
PubMed link      E-mail link

Reference Number: 345
Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res64, 7962-70 (2004)
PubMed link      E-mail link

Reference Number: 346
Welm AL, Kim S, Welm BE, Bishop JM. MET and MYC cooperate in mammary tumorigenesis. Proc Natl Acad Sci U S A. 102, 4324-9 (2005)
PubMed link      E-mail link

Reference Number: 358
Khoury H, Naujokas MA, Zuo D, Sangwan V, Frigault MM, Petkiewicz S, Dankort DL, Muller WJ, Park M. HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell. 16 550-61(2005)
PubMed link      E-mail link

Reference Number: 365
Bertotti A, Comoglio PM, Trusolino L. Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. Cancer Res. 65, 10674-9 (2005)
PubMed link      E-mail link

Reference Number: 368
Smolen GA, Muir B, Mohapatra G, Barmettler A, Kim WJ, Rivera MN, Haserlat SM, Okimoto RA, Kwak E, Dahiya S, Garber JE, Bell DW, Sgroi DC, Chin L, Deng CX, Haber DA. Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res. 66, 3452-5 (2006)
PubMed link      E-mail link

Reference Number: 463
Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mansel RE, Mason MD. The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo. Int J Mol Med. 16, 723-8 (2005)
PubMed link      E-mail link

Reference Number: 964
Graveel CR, DeGroot JD, Sigler RE, Vande Woude GF. Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles. PLoS One. 5, e13586 (2010)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 1243
Accornero P, Miretti S, Bersani F, Quaglino E, Martignani E, Baratta M. Met receptor acts uniquely for survival and morphogenesis of EGFR-dependent normal mammary epithelial and cancer cells. PLoS One. 7, e44982 (2012)
PubMed link      E-mail link

Reference Number: 1267
Gastaldi S, Sassi F, Accornero P, Torti D, Galimi F, Migliardi G, Molyneux G, Perera T, Comoglio PM, Boccaccio C, Smalley MJ, Bertotti A, Trusolino L. Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. Oncogene. 32, 1428-40 (2013)
PubMed link      E-mail link

Reference Number: 1340
Knight JF, Lesurf R, Zhao H, Pinnaduwage D, Davis RR, Saleh SM, Zuo D, Naujokas MA, Chughtai N, Herschkowitz JI, Prat A, Mulligan AM, Muller WJ, Cardiff RD, Gregg JP, Andrulis IL, Hallett MT, Park M. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proc Natl Acad Sci U S A. 110, E1301-10 (2013)
PubMed link      E-mail link

Reference Number: 1359
Regan Anderson TM1, Peacock DL, Daniel AR, Hubbard GK, Lofgren KA, Girard BJ, Schörg A, Hoogewijs D, Wenger RH, Seagroves TN, Lange CA. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression. Cancer Res. 73, 5810-20 (2013)
PubMed link      E-mail link

Reference Number: 1451
Sundaram S1, Freemerman AJ, Johnson AR, Milner JJ, McNaughton KK, Galanko JA, Bendt KM, Darr DB, Perou CM, Troester MA, Makowski L. Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basal-like breast cancer. Breast Cancer Res Treat. 142, 489-503 (2013)
PubMed link      E-mail link

Reference Number: 1568
Maroni P, Bendinelli P, Matteucci E, Locatelli A, Nakamura T, Scita G, Desiderio MA. Osteolytic bone metastasis is hampered by impinging on the interplay among autophagy, anoikis and ossification. Cell Death Dis. 5, e1005 (2014)
PubMed link      E-mail link

Reference Number: 1570
Holland JD, Györffy B, Vogel R, Eckert K, Valenti G, Fang L, Lohneis P, Elezkurtaj S, Ziebold U, Birchmeier W. Combined Wnt/ß-catenin, Met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome. Cell Rep. 5, 1214-27 (2013)
PubMed link      E-mail link

Reference Number: 1602
Qin Y, McAllister SS. SPSB1 may have MET its match during breast cancer recurrence. Cancer Discov. 4, 760-1 (2014)
PubMed link      E-mail link

Cervical

Reference Number: 1558
Chen XP, Ren XP, Lan JY, Chen YG, Shen ZJ. Analysis of HGF, MACC1, C-met and apoptosis-related genes in cervical carcinoma mice. Mol Biol Rep. 41, 1247-56 (2014)
PubMed link      E-mail link

Cholangiocarcinoma

Reference Number: 30
Radaeva, S., Ferreira-Gonzalez, A. & Sirica, A. E. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. Hepatology 29, 1453-62. (1999).
PubMed link      E-mail link

Chronic Myeloid Leukemia

Colorectal

Reference Number: 39
Shimizu, S. et al. In vivo and in vitro interactions between human colon carcinoma cells and hepatic stellate cells. Jpn J Cancer Res 91, 1285-95. (2000).
PubMed link      E-mail link

Reference Number: 218
Herynk, M.H. et al. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells.  Cancer Res 63:2990-6 (2003).
PubMed link      E-mail link

Reference Number: 219
Long, I.S. et al. Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo. Mol Cancer Res 1:393-401 (2003).
PubMed link      E-mail link

Reference Number: 311
Boon EM, Kovarikova M, Derksen PW, van der Neut R. MET signalling in primary colon epithelial cells leads to increased transformation irrespective of aberrant Wnt signalling. Br J Cancer92, 1078-83 (2005)

PubMed link      E-mail link

Reference Number: 342
Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, Comoglio PM, Michieli P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest. 114, 1418-32 (2004)
PubMed link      E-mail link

Reference Number: 362
Yoshimura M, Fujiwara H, Kubota T, Amaike H, Takashima K, Inada S, Atsuji K, Araki Y, Matsumoto K, Nakamura T, Yamagishi H. Possible inhibition of cancer cell adhesion to the extracellular matrix in NK4-induced suppression of peritoneal implantation. Anticancer Res. 25, 3847-54 (2005) Erratum in: Anticancer Res. 26, 445 (2006)
PubMed link      E-mail link

Reference Number: 595
Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T. Inhibition of colon cancer growth and metastasis by NK4 gene repetitive delivery in mice. Biochem Biophys Res Commun. 358, 117-23 (2007)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 1109
Yamaji N, Ido A, Moriuchi A, Numata M, Setoyama H, Tamai T, Funakawa K, Fujita H, Sakiyama T, Uto H, Oketani M, Tsubouchi H. Hepatocyte growth factor ameliorates mucosal injuries leading to inhibition of colon cancer development in mice. Oncol Rep. 26, 335-41 (2011)
PubMed link      E-mail link

Reference Number: 1494
Swietlicki EA, Bala S, Lu J, Shaker A, Kularatna G, Levin MS, Rubin DC. Epimorphin deletion inhibits polyposis in the Apcmin/ mouse model of colon carcinogenesis via decreased myofibroblast HGF secretion. Am J Physiol Gastrointest Liver Physiol. 305, G564-72 (2013)
PubMed link      E-mail link

Reference Number: 1770
Wang GS, Zhao JL, Li H. Treatment with Lingqi capsules suppresses colorectal cancer by inhibiting the hepatocyte growth factor/c Met signal transduction pathway. Mol Med Rep. 11, 1865-70 (2015)
PubMed link      E-mail link

Reference Number: 1833
Sun Y, Sun L, An Y, Shen X. Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model. Med Sci Monit. 21, 2316-21 (2015)
PubMed link      E-mail link

Reference Number: 1886
Lolkema MP, Bohets HH, Arkenau HT, Lampo A, Barale E, de Jonge MJ, van Doorn L, Hellemans P, de Bono JS, Eskens FA. The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. Clin Cancer Res. 21, 2297-304 (2015)
PubMed link      E-mail link

Endometrial

Reference Number: 604
Samuelson E, Nordlander C, Levan G, Behboudi A. Amplification studies of MET and Cdk6 in a rat endometrial tumor model and their correlation to human type I endometrial carcinoma tumors. Adv Exp Med Biol. 617, 511-7 (2008)
PubMed link      E-mail link

Esophogeal

Gastric

Reference Number: 49
Seruca, R. et al. Increasing levels of MYC and MET co-amplification during tumor progression of a case of gastric cancer. Cancer Genet Cytogenet 82, 140-5 (1995).
PubMed link      E-mail link

Reference Number: 226
Kim, I.J. et al. A novel germline mutation in the MET extracellular domain in a Korean patient with the diffuse type of familial gastric cancer. J Med Genet 40:e97 (2003).
PubMed link      E-mail link

Reference Number: 316
Heideman DA, van Beusechem VW, Bloemena E, Snijders PJ, Craanen ME, Offerhaus GJ, Derksen PW, de Bruin M, Witlox MA, Molenaar B, Meijer CJ, Gerritsen WR. Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4. J Gene Med 6, 317-27 (2004)
PubMed link      E-mail link

Reference Number: 343
Ueda K, Iwahashi M, Matsuura I, Nakamori M, Nakamura M, Ojima T, Naka T, Ishida K, Matsumoto K, Nakamura T, Yamaue H. Adenoviral-mediated gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice. Eur J Cancer  40, 2135-42 (2004)
PubMed link      E-mail link

Reference Number: 345
Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res64, 7962-70 (2004)
PubMed link      E-mail link

Reference Number: 667
Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA. Quantitative PET imaging of Met-expressing human cancer xenografts with (89)Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008 May 20. [Epub ahead of print]
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Glioblastomas/Astrocytomas

Reference Number: 186
Koochekpour, S. et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57, 5391-8 (1997).
PubMed link      E-mail link

Reference Number: 196
Book, A. A., Ranganathan, S., Abounader, R., Rosen, E. & Laterra, J. Scatter factor/hepatocyte growth factor gene transfer increases rat blood-glioma barrier permeability. Brain Res 833, 173-80 (1999).
PubMed link      E-mail link

Reference Number: 197
Bowers, D. C. et al. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT- dependent pathways. Cancer Res 60, 4277-83. (2000).
PubMed link      E-mail link

Reference Number: 198
Cao, B. et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A 98, 7443-8 (2001).
PubMed link      E-mail link

Reference Number: 200
Laterra, J. et al. Scatter factor/hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth. Biochem Biophys Res Commun 235, 743-7 (1997).
PubMed link      E-mail link

Reference Number: 201
Laterra, J. et al. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab Invest 76, 565-77. (1997).
PubMed link      E-mail link

Reference Number: 326
Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, Cao B, Tsarfaty G, Wang LM, Hay R, Vande Woude GF Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 24, 101-6 (2005)
PubMed link      E-mail link

Reference Number: 345
Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res64, 7962-70 (2004)
PubMed link      E-mail link

Reference Number: 1194
Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA, Park M, Bergers G. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell. 22, 21-35 (2012)
PubMed link      E-mail link

Reference Number: 1503
Rex K, Lewis XZ, Gobalakrishnan S, Glaus C, Silva MD, Radinsky R, Burgess TL, Gambhir SS, Coxon A. Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model. Nucl Med Biol. 40, 458-63 (2013)
PubMed link      E-mail link

Head and Neck

Reference Number: 667
Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA. Quantitative PET imaging of Met-expressing human cancer xenografts with (89)Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008 May 20. [Epub ahead of print]
PubMed link      E-mail link

Kaposi's Sarcoma

Reference Number: 159
Montaldo, F. et al. Expression of functional tyrosine kinases on immortalized Kaposi's sarcoma cells. J Cell Physiol 184, 246-54 (2000).
PubMed link      E-mail link

Kidney

Reference Number: 220
Miyata, Y. et al. Overexpression of hepatocyte growth factor receptor in renal carcinoma cells indirectly stimulates tumor growth in vivo. Biochem Biophys Res Commun 302:892-7 (2003). 
PubMed link      E-mail link

Reference Number: 256
Zisman A, Pantuck AJ, Bui MH, Said JW, Caliliw RR, Rao N, Shintaku P, Berger F, Gambhir SS, Belldegrun AS. LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen. Cancer Res 63:4952-9 (2003).
PubMed link      E-mail link

Reference Number: 330
Graveel C, Su Y, Koeman J, Wang LM, Tessarollo L, Fiscella M, Birchmeier C, Swiatek P, Bronson R, Vande Woude G.  Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A 101, 17198-203 (2004)


PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 986
Graveel CR, DeGroot JD, Sigler RE, Vande Woude GF. Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles. PLoS One. 5, e13586 (2010)
PubMed link      E-mail link

Reference Number: 1623
Du T, Ju G, Wu S, Cheng Z, Cheng J, Zou X, Zhang G, Miao S, Liu G, Zhu Y. Microvesicles derived from human Wharton's jelly mesenchymal stem cells promote human renal cancer cell growth and aggressiveness through induction of hepatocyte growth factor. PLoS One. 9, e96836 (2014)
PubMed link      E-mail link

Leiomyosarcoma

Reference Number: 114
Jeffers, M., Rong, S. & Vande Woude, G. F. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16, 1115-25 (1996).
PubMed link      E-mail link

Reference Number: 326
Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, Cao B, Tsarfaty G, Wang LM, Hay R, Vande Woude GF Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 24, 101-6 (2005)
PubMed link      E-mail link

Reference Number: 345
Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res64, 7962-70 (2004)
PubMed link      E-mail link

Reference Number: 353
Jiao Y, Zhao P, Zhu J, Grabinski T, Feng Z, Guan X, Skinner RS, Gross MD, Hay RV, Tachibana H, Cao B. Construction of human naive Fab library and characterization of anti-met Fab fragment generated from the library. Mol Biotechnol. 31, 41-54 (2005)
PubMed link      E-mail link

Liver

Reference Number: 22
Jakubczak, J. L., LaRochelle, W. J. & Merlino, G. NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivo. Mol Cell Biol 18, 1275-83. (1998).
PubMed link      E-mail link

Reference Number: 79
Amicone, L. et al. Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: importance of TGF-beta signalling in the control of liver homeostasis and transformation. Oncogene 21, 1335-45 (2002).
PubMed link      E-mail link

Reference Number: 80
Bell, A., Chen, Q., DeFrances, M. C., Michalopoulos, G. K. & Zarnegar, R. The five amino acid-deleted isoform of hepatocyte growth factor promotes carcinogenesis in transgenic mice. Oncogene 18, 887-95 (1999).
PubMed link      E-mail link

Reference Number: 81
Horiguchi, N. et al. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene 21, 1791-9 (2002).
PubMed link      E-mail link

Reference Number: 82
Nakayama, N. et al. Hepatocyte growth factor and c-met expression in Long-Evans Cinnamon rats with spontaneous hepatitis and hepatoma. Hepatology 24, 596-602. (1996).
PubMed link      E-mail link

Reference Number: 83
Price, J. A. et al. . Hepatology 36, 1089-97. (2002).
PubMed link      E-mail link

Reference Number: 84
Sakata, H. et al. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ 7, 1513-23 (1996).
PubMed link      E-mail link

Reference Number: 85
Santoni-Rugiu, E. et al. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc Natl Acad Sci U S A 93, 9577-82. (1996).
PubMed link      E-mail link

Reference Number: 86
Shiota, G., Kawasaki, H., Nakamura, T. & Schmidt, E. V. Inhibitory effect of hepatocyte growth factor on metastasis of hepatocellular carcinoma in transgenic mice. Res Commun Mol Pathol Pharmacol 91, 33-9 (1996).
PubMed link      E-mail link

Reference Number: 251
Scarpino S, D'Alena FC, Di Napoli A, Ballarini F, Prat M, Ruco LP. Papillary carcinoma of the thyroid: evidence for a role for hepatocyte growth factor (HGF) in promoting tumour angiogenesis. J Pathol 199:243-50 (2003).
PubMed link      E-mail link

Reference Number: 344
Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G, Sottile A, Naldini L, Comoglio PM. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature  434, 396-400 (2005)
PubMed link      E-mail link

Reference Number: 403
Zhang SZ, Pan FY, Xu JF, Yuan J, Guo SY, Dai G, Xue B, Shen WG, Wen CJ, Zhao DH, Li CJ. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther. 4, 1577-84 (2005)
PubMed link      E-mail link

Reference Number: 469
Jo J, Yamamoto M, Matsumoto K, Nakamura T, Tabata Y. Liver targeting of plasmid DNA with a cationized pullulan for tumor suppression. J Nanosci Nanotechnol. 6, 2853-9 (2006)
PubMed link      E-mail link

Reference Number: 471
Tward AD, Jones KD, Yant S, Kay MA, Wang R, Bishop JM. Genomic progression in mouse models for liver tumors. Cold Spring Harb Symp Quant Biol. 70, 217-24 (2005)
PubMed link      E-mail link

Reference Number: 472
Son G, Hirano T, Seki E, Iimuro Y, Nukiwa T, Matsumoto K, Nakamura T, Fujimoto J. Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice. J Hepatol. 45, 688-95 (2006)
PubMed link      E-mail link

Reference Number: 474
Nakanishi C, Moriuchi A, Ido A, Numata M, Kim ID, Kusumoto K, Hasuike S, Abe H, Nagata K, Akiyama Y, Uto H, Kataoka H, Tsubouchi H. Effect of hepatocyte growth factor on endogenous hepatocarcinogenesis in rats fed a choline-deficient L-amino acid-defined diet. Oncol Rep. 16 25-31 (2006)
PubMed link      E-mail link

Reference Number: 540
Yoshida Y, Hirano T, Son G, Iimuro Y, Imado T, Iwasaki T, Fujimoto J. Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease. Am J Physiol Gastrointest Liver Physiol. 293, G1114-23 (2007)
PubMed link      E-mail link

Reference Number: 558
Meredith K, Haemmerich D, Qi C, Mahvi D. Hepatic resection but not radiofrequency ablation results in tumor growth and increased growth factor expression. Ann Surg. 245, 771-6 (2007)
PubMed link      E-mail link

Reference Number: 573
Isbert C, Ritz JP, Roggan A, Schuppan D, Ajubi N, Buhr HJ, Hohenberger W, Germer CT. Laser-induced thermotherapy (LITT) elevates mRNA expression of connective tissue growth factor (CTGF) associated with reduced tumor growth of liver metastases compared to hepatic resection. Lasers Surg Med. 39, 42-50 (2007)
PubMed link      E-mail link

Reference Number: 611
Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A. 104, 14771-6 (2007)
PubMed link      E-mail link

Reference Number: 632
Takami T, Kaposi-Novak P, Uchida K, Gomez-Quiroz LE, Conner EA, Factor VM, Thorgeirsson SS. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res. 67, 9844-51 (2007)
PubMed link      E-mail link

Reference Number: 633
Towner RA, Smith N, Tesiram YA, Abbott A, Saunders D, Blindauer R, Herlea O, Silasi-Mansat R, Lupu F. In vivo detection of c-MET expression in a rat hepatocarcinogenesis model using molecularly targeted magnetic resonance imaging. Mol Imaging. 6, 18-29 (2007)
PubMed link      E-mail link

Reference Number: 644
Takashima K, Ito Y, Gonzalez FJ, Nakajima T. Different mechanisms of DEHP-induced hepatocellular adenoma tumorigenesis in wild-type and Ppar alpha-null mice. J Occup Health. 50, 169-80 (2008)
PubMed link      E-mail link

Reference Number: 663
Takahara T, Xue F, Mazzone M, Yata Y, Nonome K, Kanayama M, Kawai K, Pisacane AM, Takahara S, Li XK, Comoglio PM, Sugiyama T, Michieli P. Metron factor-1 prevents liver injury without promoting tumor growth and metastasis. Hepatology. 47, 2010-25 (2008)
PubMed link      E-mail link

Reference Number: 684
Huh CG, Factor VM, Sánchez A, Uchida K, Conner EA, Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A. 101, 4477-82 (2004)
PubMed link      E-mail link

Reference Number: 852
Piscaglia AC, Shupe TD, Pani G, Tesori V, Gasbarrini A, Petersen BE. Establishment of cancer cell lines from rat hepatocholangiocarcinoma and assessment of the role of granulocyte-colony stimulating factor and hepatocyte growth factor in their growth, motility and survival. J Hepatol. 51, 77-92 (2009)
PubMed link      E-mail link

Reference Number: 901
Patil MA, Lee SA, Macias E, Lam ET, Xu C, Jones KD, Ho C, Rodriguez-Puebla M, Chen X. Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. Cancer Res. 69, 253-61 (2009)
PubMed link      E-mail link

Reference Number: 909
Marx-Stoelting P, Borowiak M, Knorpp T, Birchmeier C, Buchmann A, Schwarz M. Hepatocarcinogenesis in mice with a conditional knockout of the hepatocyte growth factor receptor c-Met. Int J Cancer. 124, 1767-72 (2009)
PubMed link      E-mail link

Reference Number: 946
Kubo E, Yoshikawa N, Kunitomo M, Kagota S, Shinozuka K, Nakamura K. Inhibitory effect of Cordyceps sinensis on experimental hepatic metastasis of melanoma by suppressing tumor cell invasion. Anticancer Res. 30, 3429-33 (2010)
PubMed link      E-mail link

Reference Number: 1034
Ivanovska I, Zhang C, Liu AM, Wong KF, Lee NP, Lewis P, Philippar U, Bansal D, Buser C, Scott M, Mao M, Poon RT, Fan ST, Cleary MA, Luk JM, Dai H. Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma. PLoS One. 6, e24582 (2011)
PubMed link      E-mail link

Reference Number: 1386
Ogunwobi OO1, Puszyk W, Dong HJ, Liu C. Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma. PLoS One. 8, e63765 (2013)
PubMed link      E-mail link

Reference Number: 1435
Shang N, Arteaga M, Zaidi A, Stauffer J, Cotler SJ, Zeleznik-Le NJ, Zhang J, Qiu W. FAK is required for c-Met/ß-catenin-driven hepatocarcinogenesis. Hepatology. 61, 214-26 (2015)
PubMed link      E-mail link

Reference Number: 1457
Harun N, Costa P, Christophi C. Tumour growth stimulation following partial hepatectomy in mice is associated with increased upregulation of c-Met. Clin Exp Metastasis. 31, 1-14 (2014)
PubMed link      E-mail link

Reference Number: 1685
Peterson EA, Teffera Y, Albrecht BK, Bauer D, Bellon SF, Boezio A, Boezio C, Broome MA, Choquette D, Copeland KW, Dussault I, Lewis R, Lin MH, Lohman J, Liu J, Potashman M, Rex K, Shimanovich R, Whittington DA, Vaida KR, Harmange JC. Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors. J Med Chem. 58, 2417-30 (2015)
PubMed link      E-mail link

Lung

Reference Number: 98
Pilewski, J. M., Bumbalo, T. S., 3rd, Davis, A. G. & Siegfried, J. M. Hepatocyte growth factor promotes tumor growth in a novel in vivo model of human lung cancer. Am J Respir Cell Mol Biol 24, 556-62 (2001).
PubMed link      E-mail link

Reference Number: 99
Rygaard, K., Nakamura, T. & Spang-Thomsen, M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 67, 37-46 (1993).
PubMed link      E-mail link

Reference Number: 100
Saijo, Y. et al. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol 169, 469-75 (2002).
PubMed link      E-mail link

Reference Number: 101
To, C., Seiden, I., Liu, N., Wigle, D. & Tsao, M. S. High expression of Met/hepatocyte growth factor receptor suppresses tumorigenicity in NCI-H1264 lung carcinoma cells. Exp Cell Res 273, 45-53 (2002).
PubMed link      E-mail link

Reference Number: 102
Yamaura, T. et al. Solitary lung tumors and their spontaneous metastasis in athymic nude mice orthotopically implanted with human non-small cell lung cancer. Neoplasia 2, 315-24 (2000).
PubMed link      E-mail link

Reference Number: 103
Yi, S. & Tsao, M. S. Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia 2, 226-34 (2000).
PubMed link      E-mail link

Reference Number: 225

Ma, P.C. et al.  c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63:6272-81 (2003).


PubMed link      E-mail link

Reference Number: 341
Zaffaroni D, Spinola M, Galvan A, Falvella FS, Pazzaglia S, Saran A, Mancuso MT, Galbiati F, Pignatiello C, Cabrera W, Ibanez O, Manenti G, Dragani TA. Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis. Oncogene  24, 1084-90 (2005)
PubMed link      E-mail link

Reference Number: 342
Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, Comoglio PM, Michieli P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest. 114, 1418-32 (2004)
PubMed link      E-mail link

Reference Number: 387
Stabile LP, Lyker JS, Land SR, Dacic S, Zamboni BA, Siegfried JM. Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis. Mar 2; [Epub ahead of print] (2006)
PubMed link      E-mail link

Reference Number: 571
Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R, Karczmar G, Salgia R. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 67, 3529-34 (2007)
PubMed link      E-mail link

Reference Number: 678
Siddiqui SS, Loganathan S, Krishnaswamy S, Faoro L, Jagadeeswaran R, Salgia R. C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biol Ther. 7, 856-63 (2008)
PubMed link      E-mail link

Reference Number: 835
Navab R, Liu J, Seiden-Long I, Shih W, Li M, Bandarchi B, Chen Y, Lau D, Zu YF, Cescon D, Zhu CQ, Organ S, Ibrahimov E, Ohanessian D, Tsao MS. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia. 11, 1292-300 (2009)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 986
Graveel CR, DeGroot JD, Sigler RE, Vande Woude GF. Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles. PLoS One. 5, e13586 (2010)
PubMed link      E-mail link

Reference Number: 1002
Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, Safe S, Sheikh-Hamad D, Abudayyeh A, Alvarado B, Abdelrahim M. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs. 29, 41-51 (2011)
PubMed link      E-mail link

Reference Number: 1089
Kishi Y, Kuba K, Nakamura T, Wen J, Suzuki Y, Mizuno S, Nukiwa T, Matsumoto K, Nakamura T. Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models. Cancer Sci. 100, 1351-8 (2009)
PubMed link      E-mail link

Reference Number: 1153
Bowles DW, Weickhardt AJ, Doebele RC, Camidge DR, Jimeno A. Crizotinib for the treatment of patients with advanced non-small cell lung cancer. Drugs Today (Barc). 48, 271-82 (2012)
PubMed link      E-mail link

Reference Number: 1488
Zhou JY, Chen X, Zhao J, Bao Z, Chen X, Zhang P, Liu ZF, Zhou JY. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. Cancer Lett. 351, 265-71 (2014)
PubMed link      E-mail link

Reference Number: 1501
Zhang XC, Zhang J, Li M, Huang XS, Yang XN, Zhong WZ, Xie L, Zhang L, Zhou M, Gavine P, Su X, Zheng L, Zhu G, Zhan P, Ji Q, Wu YL. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies. J Transl Med. 11, 168 (2013)
PubMed link      E-mail link

Reference Number: 1738
Sakamoto S, Inoue H, Ohba S, Kohda Y, Usami I, Masuda T, Kawada M, Nomoto A. New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice. Cancer Sci. 106, 367-74 (2015)
PubMed link      E-mail link

Reference Number: 1755
Sakamoto S, Inoue H, Ohba S, Kohda Y, Usami I, Masuda T, Kawada M, Nomoto A. New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice. Cancer Sci. 106, 367-74 (2015)
PubMed link      E-mail link

Reference Number: 1779
Wu H, Fan F, Liu Z, Shen C, Wang A, Lu Y. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway. Cancer Chemother Pharmacol. 76, 307-15 (2015)
PubMed link      E-mail link

Reference Number: 1800
Chen QY, Jiao DM, Yan L, Wu YQ, Hu HZ, Song J, Yan J, Wu LJ, Xu LQ, Shi JG. Comprehensive gene and microRNA expression profiling reveals miR-206 inhibits MET in lung cancer metastasis. Mol Biosyst. 11, 2290-302 (2015)
PubMed link      E-mail link

Lymphomas

Reference Number: 179
Weimar, I. S. et al. HGF/SF and its receptor c-MET play a minor role in the dissemination of human B-lymphoma cells in SCID mice. Br J Cancer 81, 43-53 (1999).
PubMed link      E-mail link

Reference Number: 339
Graveel CR, London CA, Vande Woude GF. A mouse model of activating Met mutations. Cell Cycle4, 518-20. Epub 2005 (2005)


PubMed link      E-mail link

Reference Number: 682
Accornero P, Lattanzio G, Mangano T, Chiarle R, Taulli R, Bersani F, Forni PE, Miretti S, Scuoppo C, Dastrù W, Christensen JG, Crepaldi T, Ponzetto C. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors. Clin Cancer Res. 14, 2220-6 (2008)
PubMed link      E-mail link

Reference Number: 1747
Nakamura M, Takahashi T, Matsui H, Baniwa Y, Takahashi S, Murayama SY, Serizawa H, Suzuki H, Hibi T. Alteration of angiogenesis in Helicobacter heilmannii-induced mucosa-associated lymphoid tissue lymphoma: interaction with c-Met and hepatocyte growth factor. J Gastroenterol Hepatol. 29 Suppl 4:70-6 (2014)
PubMed link      E-mail link

Melanoma

Reference Number: 28
Takayama, H. et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 94, 701-6 (1997).
PubMed link      E-mail link

Reference Number: 206
Noonan, F. P., Otsuka, T., Bang, S., Anver, M. R. & Merlino, G. Accelerated ultraviolet radiation-induced carcinogenesis in hepatocyte growth factor/scatter factor transgenic mice. Cancer Res 60, 3738-43 (2000).
PubMed link      E-mail link

Reference Number: 207
Noonan, F. P., Dudek, J., Merlino, G. & De Fabo, E. C. Animal models of melanoma: an HGF/SF transgenic mouse model may facilitate experimental access to UV initiating events. Pigment Cell Res 16, 16-25. (2003).
PubMed link      E-mail link

Reference Number: 208
Otsuka, T. et al. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res 58, 5157-67 (1998).
PubMed link      E-mail link

Reference Number: 209
Recio, J. A. & Merlino, G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 21, 1000-8. (2002).
PubMed link      E-mail link

Reference Number: 210
Yu, Y. & Merlino, G. Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model. Cancer Res 62, 2951-6. (2002).
PubMed link      E-mail link

Reference Number: 412
Wolnicka-Glubisz A, Noonan FP. Neonatal susceptibility to UV induced cutaneous malignant melanoma in a mouse model. Photochem Photobiol Sci. 5 254-60 (2006)
PubMed link      E-mail link

Reference Number: 524
Tormo D, Ferrer A, Gaffal E, Wenzel J, Basner-Tschakarjan E, Steitz J, Heukamp LC, Gütgemann I, Buettner R, Malumbres M, Barbacid M, Merlino G, Tüting T. Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation. Am J Pathol. 169, 665-72 (2006)
PubMed link      E-mail link

Reference Number: 525
Tormo D, Ferrer A, Bosch P, Gaffal E, Basner-Tschakarjan E, Wenzel J, Tüting T. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res. 66, 5427-35 (2006)
PubMed link      E-mail link

Reference Number: 605
Florell SR, Thomas J, Grossman D. Predominant formation of heavily pigmented dermal melanocytomas resembling 'animal-type' melanomas in hepatocyte growth factor (C57BL/6 x C3H)F1 mice following neonatal UV irradiation. J Cutan Pathol. 34, 667-74 (2007)
PubMed link      E-mail link

Reference Number: 868
Kenessey I, Keszthelyi M, Krámer Z, Berta J, Adám A, Dobos J, Mildner M, Flachner B, Cseh S, Barna G, Szokol B, Orfi L, Kéri G, Döme B, Klepetko W, Tímár J, Tóvári J. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma. Curr Cancer Drug Targets. 10, 332-42 (2010)
PubMed link      E-mail link

Reference Number: 1277
Jarrett SG, Novak M, Harris N, Merlino G, Slominski A, Kaetzel DM. NM23 deficiency promotes metastasis in a UV radiation-induced mouse model of human melanoma. Clin Exp Metastasis. 30, 25-36 (2013)
PubMed link      E-mail link

Reference Number: 1606
Wolnicka-Glubisz A, Strickland FM, Wielgus A, Anver M, Merlino G, De Fabo EC, Noonan FP. A melanin-independent interaction between Mc1r and Met signaling pathways is required for HGF-dependent melanoma. Int J Cancer. 136, 752-60 (2015)
PubMed link      E-mail link

Mesothelioma

Reference Number: 986
Graveel CR, DeGroot JD, Sigler RE, Vande Woude GF. Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles. PLoS One. 5, e13586 (2010)
PubMed link      E-mail link

Reference Number: 1468
Menges CW, Kadariya Y, Altomare D, Talarchek J, Neumann-Domer E, Wu Y, Xiao GH, Shapiro IM, Kolev VN, Pachter JA, Klein-Szanto AJ, Testa JR. Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. Cancer Res. 74, 1261-71 (2014)
PubMed link      E-mail link

Reference Number: 1702
Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, Kindler HL, Salgia R. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One. 9(9):e105919 (2014)
PubMed link      E-mail link

MFH/Fibrosarcoma

Reference Number: 64
Jeffers, M. et al. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A 95, 14417-22 (1998).
PubMed link      E-mail link

Reference Number: 152
Helou, K. et al. Amplification and overexpression of the hepatocyte growth factor receptor (HGFR/MET) in rat DMBA sarcomas. Oncogene 18, 3226-34. (1999).
PubMed link      E-mail link

Reference Number: 153
Helou, K., Walentinsson, A., Kost-Alimova, M. & Levan, G. Hgfr/Met oncogene acts as target for gene amplification in DMBA-induced rat sarcomas: free chromatin fluorescence in situ hybridization analysis of amplicon arrays in homogeneously staining regions. Genes Chromosomes Cancer 30, 416-20. (2001).
PubMed link      E-mail link

Reference Number: 154
Rong, S. et al. Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res 55, 1963-70 (1995).
PubMed link      E-mail link

Reference Number: 155
Webb, C. P. et al. Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene 17, 2019-25 (1998).
PubMed link      E-mail link

Reference Number: 349
Sjoling A, Walentinsson A, Nordlander C, Karlsson A, Behboudi A, Samuelson E, Levan G, Rohme D. Assessment of allele dosage at polymorphic microsatellite loci displaying allelic imbalance in tumors by means of quantitative competitive-polymerase chain reaction. Cancer Genet Cytogenet157, 97-103 (2005)
PubMed link      E-mail link

Multiple Myeloma

Reference Number: 171
Hjorth-Hansen, H. et al. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 14, 256-63. (1999).
PubMed link      E-mail link

Nasopharyngeal

Osteosarcoma

Reference Number: 145
Ferracini, R. et al. MET oncogene aberrant expression in canine osteosarcoma. J Orthop Res 18, 253-6. (2000).
PubMed link      E-mail link

Reference Number: 821
Fieten H, Spee B, Ijzer J, Kik MJ, Penning LC, Kirpensteijn J. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma. Vet Pathol. 46, 869-77 (2009)
PubMed link      E-mail link

Reference Number: 822
De Maria R, Miretti S, Iussich S, Olivero M, Morello E, Bertotti A, Christensen JG, Biolatti B, Levine RA, Buracco P, Di Renzo MF.
met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma. J Pathol. 218, 399-408 (2009)

PubMed link      E-mail link

Reference Number: 990
Tsubaki M, Yamazoe Y, Yanae M, Satou T, Itoh T, Kaneko J, Kidera Y, Moriyama K, Nishida S. Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-ß as angiogenic factors in mouse osteosarcoma. Cytokine. 54, 100-7 (2011)
PubMed link      E-mail link

Ovarian

Reference Number: 103
Yi, S. & Tsao, M. S. Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia 2, 226-34 (2000).
PubMed link      E-mail link

Pancreas/Gall Bladder

Reference Number: 114
Jeffers, M., Rong, S. & Vande Woude, G. F. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16, 1115-25 (1996).
PubMed link      E-mail link

Reference Number: 115
Jeffers, M. et al. Hepatocyte growth factor/scatter factor-Met signaling induces proliferation, migration, and morphogenesis of pancreatic oval cells. Cell Growth Differ 7, 1805-13 (1996).
PubMed link      E-mail link

Reference Number: 391
Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res. 65, 7775-81 (2005)
PubMed link      E-mail link

Reference Number: 393
Murakami M, Nagai E, Mizumoto K, Saimura M, Ohuchida K, Inadome N, Matsumoto K, Nakamura T, Maemondo M, Nukiwa T, Tanaka M. Suppression of metastasis of human pancreatic cancer to the liver by transportal injection of recombinant adenoviral NK4 in nude mice. Int J Cancer. 117, 160-5 (2005)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 1317
Sennino B, Ishiguro-Oonuma T, Schriver BJ, Christensen JG, McDonald DM. Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res. 73, 3692-703 (2013)
PubMed link      E-mail link

Prostate

Reference Number: 126
Tam, N. N., Chung, S. S., Lee, D. T. & Wong, Y. C. Aberrant expression of hepatocyte growth factor and its receptor, c- Met, during sex hormone-induced prostatic carcinogenesis in the Noble rat. Carcinogenesis 21, 2183-91. (2000).
PubMed link      E-mail link

Reference Number: 326
Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, Cao B, Tsarfaty G, Wang LM, Hay R, Vande Woude GF Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 24, 101-6 (2005)
PubMed link      E-mail link

Reference Number: 345
Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res64, 7962-70 (2004)
PubMed link      E-mail link

Reference Number: 374
Hay RV, Cao B, Skinner RS, Su Y, Zhao P, Gustafson MF, Qian CN, Teh BT, Knudsen BS, Resau JH, Shen S, Waters DJ, Gross MD, Vande Woude GF. Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek). Clin Cancer Res. 11, 7064s-7069s (2005)
PubMed link      E-mail link

Reference Number: 463
Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mansel RE, Mason MD. The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo. Int J Mol Med. 16, 723-8 (2005)
PubMed link      E-mail link

Reference Number: 505
Ye L, Lewis-Russell JM, Davies G, Sanders AJ, Kynaston H, Jiang WG. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. Int J Oncol. 30, 521-9 (2007)
PubMed link      E-mail link

Reference Number: 1581
Chu GC, Zhau HE, Wang R, Rogatko A, Feng X, Zayzafoon M, Liu Y, Farach-Carson MC, You S, Kim J, Freeman MR, Chung LW. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr Relat Cancer. 21, 311-26 (2014)
PubMed link      E-mail link

Reference Number: 1621
Cheng CY, Hwang CI, Corney DC, Flesken-Nikitin A, Jiang L, Oner GM, Munroe RJ, Schimenti JC, Hermeking H, Nikitin AY. miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment. Cell Rep. 6, 1000-7 (2014)
PubMed link      E-mail link

Reference Number: 1650
Eswaraka J, Giddabasappa A, Han G, Lalwani K, Eisele K, Feng Z, Affolter T, Christensen J, Li G. Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer. BMC Cancer. 14, 742 (2014)
PubMed link      E-mail link

Reference Number: 1684
Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik M1, True LD, Morrissey C, Corey E, Montgomery B, Mostaghel E, Clegg N, Coleman I, Brown CM, Schneider EL, Craik C, Simon JA, Bedalov A, Nelson PS. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 4, 1310-25 (201
PubMed link      E-mail link

Reference Number: 1720
Yu Y, Chen Y, Ding G, Wang M, Wu H, Xu L, Rui X, Zhang Z A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts. Biochem Biophys Res Commun. 464, 154-60 (2015)
PubMed link      E-mail link

Rhabdomyosarcoma

Reference Number: 28
Takayama, H. et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 94, 701-6 (1997).
PubMed link      E-mail link

Reference Number: 151
Sharp, R. et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med 8, 1276-80 (2002).
PubMed link      E-mail link

Reference Number: 817
Lukasiewicz E, Miekus K, Kijowski J, Drabik G, Wilusz M, Bobis-Wozowicz S, Majka M. Inhibition of rhabdomyosarcoma's metastatic behavior through downregulation of MET receptor signaling. Folia Histochem Cytobiol. 47, 485-9 (2009)
PubMed link      E-mail link

Synovial Sarcoma

Thyroid

Wilms' Tumor

Reference Number: 375
Pinthus JH, Sheffer Y, Nagler A, Fridman E, Mor Y, Genina O, Pines M. Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression. J Urol. 174, 1527-31 (2005)
PubMed link      E-mail link